APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

5 June 2026191 pages

Choose your research edition.

Industry ResearchLive Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Analysis and Forecast 2026-2032259 pages · $4,950 USD

Market perspective

The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio) and Bacthera (Novonesis+Lonza), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Biotherapeutic Products (LBP) and Microbiome CDMO Service revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Company

Lallemand Health Solutions

Wacker Chemie AG

Biose Industrie

List Biological Labs, Inc.

NIZO

SGS (Quay Pharmaceuticals)

Assembly Biosciences, Inc.

Recipharm (Arranta Bio)

Bacthera (Novonesis+Lonza)

Smaltis

Lonza

vermicon AG

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Type

Solid Dosage Form

Liquid Dosage Form

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Application

Digestive System Diseases

Immune System Diseases

Metabolic Diseases

Other

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service industry.

Chapter 3: Detailed analysis of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live Biotherapeutic Products (LBP) and Microbiome CDMO Servicerevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Solid Dosage Form Table 3. Key Players of Liquid Dosage Form Table 4. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Digestive System Diseases Table 6. Key Players of Immune System Diseases Table 7. Key Players of Metabolic Diseases Table 8. Key Players of Other Table 9. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2021-2026) Table 12. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2027-2032) Table 14. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends Table 15. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Drivers Table 16. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Opportunities and Challenges Table 17. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Restraints Table 18. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Company (2021-2026) Table 20. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Company Head Office and Area Served Table 22. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company, Product Type & Application Table 23. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2021-2026) Table 30. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2027-2032) Table 31. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021-2026) Table 35. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2027-2032) Table 36. Lallemand Health Solutions Company Information Table 37. Lallemand Health Solutions Business Overview Table 38. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 40. Lallemand Health Solutions Recent Development Table 41. Wacker Chemie AG Company Information Table 42. Wacker Chemie AG Business Overview Table 43. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 45. Wacker Chemie AG Recent Development Table 46. Biose Industrie Company Information Table 47. Biose Industrie Business Overview Table 48. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 50. Biose Industrie Recent Development Table 51. List Biological Labs, Inc. Company Information Table 52. List Biological Labs, Inc. Business Overview Table 53. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 55. List Biological Labs, Inc. Recent Development Table 56. NIZO Company Information Table 57. NIZO Business Overview Table 58. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 60. NIZO Recent Development Table 61. SGS (Quay Pharmaceuticals) Company Information Table 62. SGS (Quay Pharmaceuticals) Business Overview Table 63. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 65. SGS (Quay Pharmaceuticals) Recent Development Table 66. Assembly Biosciences, Inc. Company Information Table 67. Assembly Biosciences, Inc. Business Overview Table 68. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 70. Assembly Biosciences, Inc. Recent Development Table 71. Recipharm (Arranta Bio) Company Information Table 72. Recipharm (Arranta Bio) Business Overview Table 73. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 75. Recipharm (Arranta Bio) Recent Development Table 76. Bacthera (Novonesis+Lonza) Company Information Table 77. Bacthera (Novonesis+Lonza) Business Overview Table 78. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 80. Bacthera (Novonesis+Lonza) Recent Development Table 81. Smaltis Company Information Table 82. Smaltis Business Overview Table 83. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 85. Smaltis Recent Development Table 86. Lonza Company Information Table 87. Lonza Business Overview Table 88. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 90. Lonza Recent Development Table 91. vermicon AG Company Information Table 92. vermicon AG Business Overview Table 93. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio Table 95. vermicon AG Recent Development Table 96. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026) & (US$ Million) Table 97. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032) & (US$ Million) Table 98. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026) & (US$ Million) Table 99. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032) & (US$ Million) Table 100. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026) Table 102. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032) Table 103. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026) & (US$ Million) Table 104. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032) & (US$ Million) Table 105. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026) & (US$ Million) Table 106. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032) & (US$ Million) Table 107. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026) Table 109. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032) Table 110. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026) & (US$ Million) Table 111. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032) & (US$ Million) Table 112. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026) & (US$ Million) Table 113. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032) & (US$ Million) Table 114. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026) & (US$ Million) Table 115. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032) & (US$ Million) Table 116. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026) & (US$ Million) Table 117. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032) & (US$ Million) Table 118. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026) Table 120. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032) Table 121. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026) & (US$ Million) Table 122. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032) & (US$ Million) Table 123. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026) & (US$ Million) Table 124. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032) & (US$ Million) Table 125. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026) Table 127. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032) Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Image Figure 2. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type: 2025 VS 2032 Figure 4. Solid Dosage Form Image Figure 5. Liquid Dosage Form Image Figure 6. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application: 2025 VS 2032 Figure 8. Digestive System Diseases Image Figure 9. Immune System Diseases Image Figure 10. Metabolic Diseases Image Figure 11. Other Image Figure 12. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 14. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region: 2025 VS 2032 Figure 15. Years Considered Figure 16. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Players in 2025 Figure 17. Global Top 5 and 10 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share by Revenue in 2025 Figure 18. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2021-2032) Figure 21. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021-2032) Figure 23. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 24. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032) Figure 25. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032) Figure 26. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032) Figure 27. United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 28. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 29. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 30. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 31. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032) Figure 32. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032) Figure 33. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032) Figure 34. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 35. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 36. U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 37. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 38. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 39. Nordic Countries Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 40. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 41. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032) Figure 42. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032) Figure 43. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 44. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032) Figure 45. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032) Figure 46. Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032) Figure 47. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 48. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 49. Taiwan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 50. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 51. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 52. Australia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 54. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032) Figure 55. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032) Figure 56. South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032) Figure 57. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 58. South Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 59. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 60. Turkey Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 61. Argentina Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 62. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 63. Egypt Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 64. Chile Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032) & (US$ Million) Figure 65. Research Process Figure 66. Key Executives Interviewed

Scope & coverage.

Types
  • Solid Dosage Form
  • Liquid Dosage Form
Applications
  • Digestive System Diseases
  • Immune System Diseases
  • Metabolic Diseases
  • Other
Companies covered
  • Lallemand Health Solutions
  • Wacker Chemie AG
  • Biose Industrie
  • List Biological Labs, Inc.
  • NIZO
  • SGS (Quay Pharmaceuticals)
  • Assembly Biosciences, Inc.
  • Recipharm (Arranta Bio)
  • Bacthera (Novonesis+Lonza)
  • Smaltis
  • Lonza
  • vermicon AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Solid Dosage Form
  5. 1.2.3 Liquid Dosage Form
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Digestive System Diseases
  9. 1.3.3 Immune System Diseases
  10. 1.3.4 Metabolic Diseases
  11. 1.3.5 Other
  12. 1.4 Global Market Growth Prospects
  13. 1.5 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Growth Trends by Region
  14. 1.5.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
  15. 1.5.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2021-2026)
  16. 1.5.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2027-2032)
  17. 1.6 Assumptions and Limitations
  18. 1.7 Study Goals and Objectives
  19. 1.8 Years Considered
2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Dynamics
  1. 2.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends
  2. 2.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Drivers
  3. 2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Opportunities and Challenges
  4. 2.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Company (2021-2026)
  2. 3.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Key Company Head office and Area Served
  4. 3.4 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company, Product Type & Application
  5. 3.5 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Tier 1, Tier 2, and Tier 3
4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Type
  1. 4.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2032)
  3. 4.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Share by Type (2021-2032)
5 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market by Application
  1. 5.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2032)
  3. 5.3 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Lallemand Health Solutions
  2. 6.1.1 Lallemand Health Solutions Company Information
  3. 6.1.2 Lallemand Health Solutions Business Overview
  4. 6.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  6. 6.1.5 Lallemand Health Solutions Recent Developments
  7. 6.2 Wacker Chemie AG
  8. 6.2.1 Wacker Chemie AG Company Information
  9. 6.2.2 Wacker Chemie AG Business Overview
  10. 6.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  12. 6.2.5 Wacker Chemie AG Recent Developments
  13. 6.3 Biose Industrie
  14. 6.3.1 Biose Industrie Company Information
  15. 6.3.2 Biose Industrie Business Overview
  16. 6.3.3 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  18. 6.3.5 Biose Industrie Recent Developments
  19. 6.4 List Biological Labs, Inc.
  20. 6.4.1 List Biological Labs, Inc. Company Information
  21. 6.4.2 List Biological Labs, Inc. Business Overview
  22. 6.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  24. 6.4.5 List Biological Labs, Inc. Recent Developments
  25. 6.5 NIZO
  26. 6.5.1 NIZO Company Information
  27. 6.5.2 NIZO Business Overview
  28. 6.5.3 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  30. 6.5.5 NIZO Recent Developments
  31. 6.6 SGS (Quay Pharmaceuticals)
  32. 6.6.1 SGS (Quay Pharmaceuticals) Company Information
  33. 6.6.2 SGS (Quay Pharmaceuticals) Business Overview
  34. 6.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  36. 6.6.5 SGS (Quay Pharmaceuticals) Recent Developments
  37. 6.7 Assembly Biosciences, Inc.
  38. 6.7.1 Assembly Biosciences, Inc. Company Information
  39. 6.7.2 Assembly Biosciences, Inc. Business Overview
  40. 6.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  42. 6.7.5 Assembly Biosciences, Inc. Recent Developments
  43. 6.8 Recipharm (Arranta Bio)
  44. 6.8.1 Recipharm (Arranta Bio) Company Information
  45. 6.8.2 Recipharm (Arranta Bio) Business Overview
  46. 6.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  48. 6.8.5 Recipharm (Arranta Bio) Recent Developments
  49. 6.9 Bacthera (Novonesis+Lonza)
  50. 6.9.1 Bacthera (Novonesis+Lonza) Company Information
  51. 6.9.2 Bacthera (Novonesis+Lonza) Business Overview
  52. 6.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  54. 6.9.5 Bacthera (Novonesis+Lonza) Recent Developments
  55. 6.10 Smaltis
  56. 6.10.1 Smaltis Company Information
  57. 6.10.2 Smaltis Business Overview
  58. 6.10.3 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  60. 6.10.5 Smaltis Recent Developments
  61. 6.11 Lonza
  62. 6.11.1 Lonza Company Information
  63. 6.11.2 Lonza Business Overview
  64. 6.11.3 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  66. 6.11.5 Lonza Recent Developments
  67. 6.12 vermicon AG
  68. 6.12.1 vermicon AG Company Information
  69. 6.12.2 vermicon AG Business Overview
  70. 6.12.3 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product Portfolio
  72. 6.12.5 vermicon AG Recent Developments
7 North America
  1. 7.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
  2. 7.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type
  3. 7.2.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026)
  4. 7.2.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032)
  5. 7.2.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032)
  6. 7.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application
  7. 7.3.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026)
  8. 7.3.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032)
  9. 7.3.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032)
  10. 7.4 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
  11. 7.4.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
  13. 7.4.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
  14. 7.4.4 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
  2. 8.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type
  3. 8.2.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026)
  4. 8.2.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032)
  5. 8.2.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032)
  6. 8.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application
  7. 8.3.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026)
  8. 8.3.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032)
  9. 8.3.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032)
  10. 8.4 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
  11. 8.4.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
  13. 8.4.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
  14. 8.4.4 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
  2. 9.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type
  3. 9.2.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026)
  4. 9.2.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032)
  5. 9.2.3 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032)
  6. 9.3 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application
  7. 9.3.1 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026)
  8. 9.3.2 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032)
  9. 9.3.3 China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
  2. 10.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type
  3. 10.2.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026)
  4. 10.2.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032)
  5. 10.2.3 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032)
  6. 10.3 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application
  7. 10.3.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026)
  8. 10.3.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032)
  9. 10.3.3 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032)
  10. 10.4 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
  11. 10.4.1 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
  13. 10.4.3 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
  14. 10.4.4 Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst